In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ImClone and Bristol: The Acquisition Fight Focuses on the Erbitux Successor

Executive Summary

ImClone chairman Carl Icahn wants Bristol-Myers Squibb to pay a lot more in order to acquire the developer of blockbuster cancer drug Erbitux. His argument: there's a lot more to ImClone than Erbitux, namely, a competitive follow-on. Bristol thinks it's already got the rights to that compound; Icahn apparently disagrees (and indeed Amgen wriggled out of a similar dispute over a follow-on with J&J). But a close reading of the Bristol/ImClone contract tends to agree with Bristol.

Related Content


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts